Streetbeat News

Stock Prices

CBNA

Chain Bridge Bancorp has announced its initial public offering (IPO) of 1.85 million shares, with an expected price range of $24 to $26 per share.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:38 pm

KZR

Kezar Life Sciences has voluntarily stopped enrollment and dosing in its Phase 2b PALIZADE trial of Zetomipzomib for active lupus nephritis patients. This decision could impact the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:35 pm

NBIX

Neurocrine Biosciences presented interim data showing significant and sustained improvements in chorea associated with Huntington's Disease through week 104, regardless of antipsychotic use.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

ASND

Ascendis Pharma presented 3-year data at ASBMR 2024, demonstrating that long-term treatment with TransCon PTH normalizes bone remodeling in adults with hypoparathyroidism.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:33 pm

ALCE

VVPR

The article highlights two oversold utility stocks, VivoPower International (VVPR) and Alternus Clean Energy (ALCE), which present potential buying opportunities. Both companies have experienced significant stock price declines and have RSI values indicating oversold conditions.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:32 pm

CLNN

Clene Inc. has announced a $7.3 million registered direct offering and concurrent private placements, issuing 742,626 shares and warrants priced at market under Nasdaq rules.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:31 pm

APLD

BTBT

BTDR

CIFR

CRVS

HUT

MSTR

STLA

VERO

Several major stocks, including Stellantis, MicroStrategy, and Bit Digital, are experiencing declines in Monday's pre-market session. Stellantis shares fell sharply after lowering its 2024 operating margin guidance. Other stocks like Bitdeer Technologies, Corvus Pharmaceuticals, and Venus Concept also saw significant pre-market losses.

Portfolio Pulse from Avi Kapoor

September 30, 2024 | 12:30 pm

CI

CVS

UNH

CVS Health is under pressure as activist investor Glenview Capital Management plans to meet with executives to discuss operational improvements. Glenview, holding a $700 million position, aims for cost-cutting and restructuring without a breakup. CVS faces challenges with declining earnings and FTC scrutiny over anti-competitive practices.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 12:26 pm

ASST

Asset Entities has announced an at-the-market offering of up to $1.79 million in Class B common stock. This move allows the company to raise capital by selling shares directly into the market at prevailing prices.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:23 pm

WINT

Windtree Therapeutics reported that serious adverse events related to worsening heart failure occurred less frequently in patients treated with Istaroxime compared to those given a placebo. The rates were 5.3% for the Istaroxime group versus 18.2% for the placebo group.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:21 pm